US Grants.gov · Aberto

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Página oficial do aviso ↗

This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations. ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).

Histórico de alterações

First seen 28 Sept 2026, last checked 22 Nov 2026. 20 recorded versions.

  • 04 Nov 2026 · 34a93931c23d
  • 22 Oct 2026 · e2364c379dc8
  • 22 Oct 2026 · d50d4aa626a4
  • 21 Oct 2026 · 5682a2adf183
  • 20 Oct 2026 · e40bed43426e
  • 19 Oct 2026 · ff716d72065a
  • 18 Oct 2026 · 87a380c58909
  • 17 Oct 2026 · 88f5bdb0b907
  • 16 Oct 2026 · 9e8f655a75df
  • 15 Oct 2026 · 5682a2adf183
  • 14 Oct 2026 · 7ce7902bb173
  • 13 Oct 2026 · b70ff8d3d0c0
  • 12 Oct 2026 · 3f2ac9b8e863
  • 11 Oct 2026 · 704220cdde7b
  • 10 Oct 2026 · b295be2b9047
  • 09 Oct 2026 · 00f24564712f
  • 08 Oct 2026 · 82381e4cefa7
  • 07 Oct 2026 · a5edf3caf3bc
  • 06 Oct 2026 · 134364f75c14
  • 05 Oct 2026 · dc65be088c3e

Report a problem with this record · How data is produced